Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

作者：David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace A. Akerley, Jessica Ruth Bauman, Ankit Bharat, Debora Santos Bruno, Joe Yujiao Chang, Lucian R. Chirieac, Thomas Anthony D’Amico, Malcolm M. DeCamp, Thomas J. Dilling, Jonathan E. Dowell, Scott N. Gettinger, Travis Edward Grotz, Matthew A. Gubens, Aparna Madhukeshwar Hegde, Rudy P. Lackner, Michael D. Lanuti, Jules Lin, Billy Wiseman Loo Jr., Christine Marie Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, José Miguel Pacheco, Sandip Pravin Patel, Gregory J. Riely, Jonathan Wesley Riess, Steven E. Schild, Theresa A. Shapiro, Aditi Puri Singh, James P. Stevenson, Alda Lui Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin H. Yau, Kristina M. Gregory, Miranda Hughes · 发表于：Journal of the National Comprehensive Cancer Network · 年份：2022 · DOI：10.6004/jnccn.2022.0025 · 被引用次数：1454 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Genomics and Diagnostics、Lung Cancer Research Studies

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) provide recommended management for patients with NSCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. Patients with metastatic lung cancer who are eligible for targeted therapies or immunotherapies are now surviving longer. This selection from the NCCN Guidelines for NSCLC focuses on targeted therapies for patients with metastatic NSCLC and actionable mutations.